GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Embecta Corp.
Embecta, spun off from Becton Dickinson, is a leader in insulin delivery products such as syringes and needles. Its share price reflects robust demand driven by the global diabetes epidemic, as well as competition from new technologies.
Share prices of companies in the market segment - Specialized medical equipment
Embecta (EMBC) is a company specializing in diabetes treatment products, primarily insulin syringes and needles, spun out of Becton, Dickinson. We classify it as a "Specialized Medical Equipment" company. The chart below reflects general trends in the diabetes medical device sector.
Broad Market Index - GURU.Markets
Embecta, a Becton Dickinson spinoff, specializes in diabetes treatment products such as syringes and needles. As a component of the GURU.Markets index, it is a leader in its niche. The chart below represents the entire market. See how Embecta shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
EMBC - Daily change in the company's share price Embecta Corp.
The daily price change of Embecta, a manufacturer of diabetes products, is a measure of its sensitivity to medical innovation. Change_co reflects the stability inherent in the chronic disease treatment market. This metric is important for analyzing companies in the medical equipment sector on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Specialized medical equipment
Embecta Corp. is a company specializing in diabetes treatment products. This chart shows the average daily volatility of the MedTech sector. Comparing it to EMBC, a spinoff from Becton Dickinson, helps to assess it as a pure-play player in this market.
Daily change in the price of a broad market stock, index - GURU.Markets
Embecta, a spinoff from Becton Dickinson, is a company focused on diabetes treatment products, specifically syringes and needles. The healthcare sector is considered relatively defensive. The chart below shows general market fluctuations, which can be used to assess how Embecta is responding to economic challenges.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Embecta Corp.
Embecta, spun off from Becton Dickinson, is now a pure-play player in the insulin injection market. Its year-over-year growth reflects stable demand driven by the growing number of people with diabetes worldwide.
Annual dynamics of market capitalization of the market segment - Specialized medical equipment
Embecta Corp., spun off from Becton Dickinson, is a pure-play player in the diabetes treatment market, primarily syringes and needles. The chart below shows how its dominant position in this mature but stable market and its efforts in new product development impact its performance in the sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Embecta, a manufacturer of products for people with diabetes, operates in the protective healthcare sector. Demand for its products (syringes, needles) is stable and independent of the economy. The company's share price performance since the spinoff reflects this stability, based on the persistent demand for its products.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Embecta Corp.
The performance of Embecta, a diabetes product manufacturer (spinned out of Becton Dickinson), depends on this market. The monthly fluctuations on the chart reflect stable demand for its insulin syringes and needles, as well as its ability to compete with new technologies like insulin pumps.
Monthly dynamics of market capitalization of the market segment - Specialized medical equipment
Embecta, a spinoff from Becton Dickinson, specializes in solutions for people with diabetes, specifically insulin delivery systems. Its growth is driven by innovation and demographic trends in healthcare. The chart shows the overall dynamics of the medical equipment sector, which is an important backdrop for evaluating this niche player.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Embecta Corp., which specializes in diabetes treatment products, operates in the stable and non-cyclical healthcare sector. Demand for its products is constant and unaffected by the economic climate. This makes the company's shares a safe haven, with monthly performance typically much smoother than the broader market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Embecta Corp.
Short-term fluctuations in Embecta, the insulin pen company spun off from Becton Dickinson, reflect the state of the diabetes treatment market. News about competition from new insulin delivery methods and data on diabetes prevalence are driving its performance.
Weekly dynamics of market capitalization of the market segment - Specialized medical equipment
Embecta and the entire diabetes care sector are responding to general demographic trends and innovation. The growing number of patients is a driver for everyone. The chart shows how the company, focused on syringe pens, competes with pump and sensor manufacturers.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Embecta, operating in the stable healthcare sector, may be less volatile than the market. Demand for its diabetes products is not dependent on the economy. The chart will show whether the company's shares truly serve as a "safe haven" during periods of market turbulence.
Market capitalization of the company, segment and market as a whole
EMBC - Market capitalization of the company Embecta Corp.
Embecta's market capitalization is the financial valuation of a company recently spun out of Becton Dickinson and focused entirely on diabetes products, primarily syringes and needles. The chart reflects the stable demand for its vital products. Its dynamics tell a story about how investors assess the prospects of this "pure" player in the vast diabetes market.
EMBC - Share of the company's market capitalization Embecta Corp. within the market segment - Specialized medical equipment
Embecta Corp. is a spinoff from Becton Dickinson, a global leader in insulin delivery products such as syringes and needles. Its share of the diabetes market is enormous. The chart below shows the impact this focused giant has on the daily lives of millions of people with diabetes.
Market capitalization of the market segment - Specialized medical equipment
Embecta, a spinoff from Becton Dickinson, focuses on diabetes treatment products, primarily syringes and needles. The chart below shows the overall market capitalization of the specialized medical equipment sector. It reflects the scale of the global diabetes epidemic, where Embecta is a key supplier.
Market capitalization of all companies included in a broad market index - GURU.Markets
The medical devices visible on the chart may be focused on specific diseases. Embecta Corp., spun off from Becton Dickinson, specializes in diabetes products such as syringes and needles. Its market capitalization reflects its leadership in this large and stable niche.
Book value capitalization of the company, segment and market as a whole
EMBC - Book value capitalization of the company Embecta Corp.
Embecta, a spinoff from Becton Dickinson, represents the legacy material foundation of diabetes care. Its book value reflects the value of the factories that produce syringes, needles, and other critical products for millions of people living with diabetes.
EMBC - Share of the company's book capitalization Embecta Corp. within the market segment - Specialized medical equipment
Embecta Corp., spun off from Becton Dickinson, is a leader in diabetes products. Its stake in the sector includes large syringe and needle manufacturing plants. This large-scale production base ensures its dominant position in the global market.
Market segment balance sheet capitalization - Specialized medical equipment
Embecta, spun off from Becton Dickinson, is a leader in insulin delivery systems. The medical equipment sector, as the chart shows, is capital-intensive. Embecta is a classic player, owning syringe and needle manufacturing plants.
Book value of all companies included in the broad market index - GURU.Markets
Embecta Corp., spun off from Becton Dickinson, is a pure-play player in the diabetes treatment market. Its book value comes from factories that produce syringes, needles, and other insulin injection products used by millions of people worldwide.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Embecta Corp.
Embecta is a manufacturer of diabetes products. Its moderate premium reflects its dominant position in the insulin syringe and needle market, which ensures stable and predictable cash flow.
Market to book capitalization ratio in a market segment - Specialized medical equipment
Embecta was spun out of Becton Dickinson and specializes in diabetes products, specifically syringes and needles. The chart shows how the market values this focused company, its dominant position in its niche, and its ability to generate stable cash flow.
Market to book capitalization ratio for the market as a whole
Embecta, a spinoff from Becton Dickinson, specializes in diabetes treatment products, primarily syringes and needles. Compared to average market valuations shown in this chart, its valuation reflects the stability of its business but also competition from new insulin delivery technologies.
Debts of the company, segment and market as a whole
EMBC - Company debts Embecta Corp.
Embecta is a company specializing in the production of products for people with diabetes, specifically syringes and needles for insulin pens. As a spinoff from a larger corporation, it can use the debt to establish independent operations and invest in R&D and marketing to strengthen its position in the diabetes treatment market.
Market segment debts - Specialized medical equipment
Embecta was spun off from Becton Dickinson and is now a company focused entirely on diabetes treatment products (such as injection pens). As a standalone company, it has its own capital structure. This chart shows its initial leverage and financial policy after the split.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Embecta Corp.
Embecta Corp. specializes in diabetes products, such as syringes and needles. This chart shows the financial structure of the company, which was spun off from a larger corporation. The level of debt with which it began independent operations is important for assessing its ability to invest in new products and compete in the diabetes market.
Market segment debt to market segment book capitalization - Specialized medical equipment
Embecta Corp., spun off from Becton Dickinson, specializes in diabetes treatment products, specifically syringes and needles. This market is stable but requires innovation. This chart shows the overall debt load in the medical device sector. It allows one to assess how the newly independent company is structuring its financial structure relative to the industry.
Debt to book value of all companies in the market
Embecta Corp. is a company specializing in diabetes products, specifically injection pens. Spun off from Becton Dickinson, it has an established business. This chart helps understand its financial policies as an independent company: how it leverages its stable cash flow and debt to drive innovation and growth.
P/E of the company, segment and market as a whole
P/E - Embecta Corp.
This chart shows the valuation of Embecta, a company specializing in diabetes products (such as syringes) spun out of Becton Dickinson. Its P/E reflects the valuation of a mature and stable business. Investors value it for the consistent demand driven by the chronic nature of the condition its products address.
P/E of the market segment - Specialized medical equipment
Embecta is a diabetes treatment company spun out of Becton Dickinson. It produces insulin syringes, pens, and other products for people with diabetes. This chart shows the average valuation for the sector, helping to understand how the market values this focused player in diabetes care.
P/E of the market as a whole
Embecta Corp., a spinoff from Becton Dickinson, is a company focused exclusively on diabetes treatment products, primarily insulin syringes and needles. Demand for its products is driven by the prevalence of diabetes and is highly stable. Its business is virtually unaffected by economic cycles, as illustrated by this chart.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Embecta Corp.
Embecta Corp. was spun off from Becton, Dickinson and is one of the largest companies in the world focused exclusively on diabetes products, primarily syringes and needles. This chart shows how the market views the future stability and growth of this focused business in light of the global diabetes epidemic.
%20P%2FE%20Embecta%20Corp.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Embecta-Corp.&v=1772513443441 "Chart of the company's future (projected) P/E Embecta Corp.")
Future (projected) P/E of the market segment - Specialized medical equipment
Embecta Corp., spun off from Becton Dickinson, is a company focused entirely on diabetes treatment products, primarily insulin syringes and needles. This chart shows general expectations for the medical device sector. EMBC's position relative to the average reflects the market's view of the future of this mature but stable business in the face of rising diabetes rates.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Specialized%20medical%20equipment&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Specialized-medical-equipment&v=1772513443494 "Future (projected) P/E graph of the market segment - Specialized medical equipment")
Future (projected) P/E of the market as a whole
Embecta Corp. specializes in products for people with diabetes, specifically syringes and needles. This is a stable market, as demand for these products is inelastic. This chart allows investors to assess the appeal of this "defensive" healthcare position against the overall market situation. In turbulent times, such companies are valued higher.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513443510 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Embecta Corp.
Embecta Corp., a spinoff from Becton Dickinson, is a company focused entirely on diabetes treatment products, primarily insulin syringes and needles. Its revenue, as shown in the chart, depends on the global prevalence of diabetes and the company's ability to maintain a leading position in this mature market.
Profit of companies in the market segment - Specialized medical equipment
Embecta Corp., spun off from Becton Dickinson, is one of the world's leading companies specializing in diabetes products such as injection pens and needles. This chart shows the collective revenue of the specialized medical equipment sector. It illustrates global trends in diabetes treatment and the financial health of companies operating in this vast market.
Overall market profit
Embecta Corp., spun off from Becton Dickinson, is a global leader in diabetes products, particularly insulin syringes. Demand for its products is stable and unaffected by economic cycles, as reflected in this chart, as diabetes treatment is a vital necessity for millions of people worldwide.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Embecta Corp.
Embecta Corp. is a company specializing in diabetes treatment products, specifically insulin syringes and needles. It was spun off from Becton, Dickinson. This chart shows analysts' future earnings expectations, which depend on stable demand for its key products in the global diabetes market.
%20profit%20of%20the%20company%20Embecta%20Corp.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Embecta-Corp.&v=1772513443563 "Graph of future (projected) profit of the company Embecta Corp.")
Future (predicted) profit of companies in the market segment - Specialized medical equipment
Embecta Corp. is a company specializing in the production of products for people with diabetes, specifically syringes and needles for insulin pens. Demand for its products is driven by the global rise in diabetes. This chart shows profitability forecasts for the medical device sector, helping to assess how Embecta compares to overall healthcare trends.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Specialized%20medical%20equipment&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Specialized-medical-equipment&v=1772513443581 "Graph of future (predicted) profits of companies in a market segment - Specialized medical equipment")
Future (predicted) profit of the market as a whole
Embecta Corp. specializes in diabetes products, specifically injection pens. Demand for these products is vital and inelastic, making it largely unaffected by economic cycles. This graph, which shows overall corporate profits, is not a significant factor in the company's business.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513443596 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Embecta Corp.
Embecta, a Becton Dickinson spinoff, specializes in diabetes products, primarily syringes and needles. This chart shows how the market values the business as a standalone entity. Investors are looking at the revenue stability provided by the chronic nature of its clients' diabetes.
P/S market segment - Specialized medical equipment
Embecta Corp. is a company specializing in the production of products for people with diabetes, specifically syringes and needles for insulin injections. Revenue is generated from sales of these consumables. This chart for the medical devices sector helps investors assess Embecta's position in the mature but stable diabetes treatment market.
P/S of the market as a whole
Embecta Corp., a spinoff from Becton Dickinson, is a company focused entirely on diabetes treatment products, primarily insulin syringes and needles. This total market revenue valuation chart helps investors understand how the company is valued, targeting the massive, ever-growing, yet highly competitive diabetes market.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Embecta Corp.
Embecta Corp., a spinoff from Becton Dickinson, is a company focused entirely on diabetes treatment products, specifically insulin syringes and needles. This chart shows how investors estimate future sales of its specialized products, reflecting their expectations for the growing number of people with diabetes worldwide.
%20P%2FS%20Embecta%20Corp.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Embecta-Corp.&v=1772513443822 "The graph of the company's future (projected) P/S Embecta Corp.")
Future (projected) P/S of the market segment - Specialized medical equipment
Embecta Corp. was spun out of Becton Dickinson as an independent company focused entirely on diabetes treatment products, such as syringes and needles for insulin pens. The company's valuation reflects its leading position in this mature market, stable cash flows, and the challenges associated with competition from new insulin delivery technologies.
%20P%2FS%20market%20segment%20graph%20-%20Specialized%20medical%20equipment&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Specialized-medical-equipment&v=1772513443831 "Future (projected) P/S market segment graph - Specialized medical equipment")
Future (projected) P/S of the market as a whole
Embecta Corp. is a company specializing in the production of diabetes treatment products, such as syringes and needles. Demand for its products is stable and driven by the chronic condition. Based on the overall outlook shown in the chart, Embecta represents the non-cyclical healthcare sector.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513443842 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Embecta Corp.
Embecta is a company specializing in diabetes products, spun out of Becton, Dickinson. This chart shows global revenue from sales of insulin syringes, pen needles, and other insulin delivery supplies. Stable demand is driven by the chronic nature of the disease.
Sales of companies in the market segment - Specialized medical equipment
Embecta (EMBC) is a company specializing in diabetes care products, specifically insulin syringes and needles. It was spun off from Becton, Dickinson and Company (BD). This metric reflects revenue in the medical device market, where Embecta is a global leader in its narrow but vital niche of diabetes care.
Overall market sales
Embecta Corp. specializes in products for people with diabetes, specifically insulin syringes and needles. Demand for its products is driven by the chronic condition and is stable. However, the overall economic situation, reflected in this chart, impacts healthcare access, insurance coverage, and patient affordability worldwide.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Embecta Corp.
Embecta Corp. is a company specializing in the production of diabetes treatment products, primarily syringes and needles for insulin injections. The company's future sales are dependent on the prevalence of diabetes and competition from alternative insulin delivery methods. This chart reflects analysts' revenue forecasts based on stable demand for its core products.
%20sales%20of%20the%20company%20Embecta%20Corp.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Embecta-Corp.&v=1772513443963 "Schedule of future (projected) sales of the company Embecta Corp.")
Future (projected) sales of companies in the market segment - Specialized medical equipment
Embecta, spun off from Becton Dickinson, is a company focused entirely on diabetes treatment, primarily producing syringes and needles for insulin administration. This forecast chart details expected sales of these key products. It shows how analysts estimate demand for traditional insulin delivery devices against the backdrop of new technologies.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Specialized%20medical%20equipment&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Specialized-medical-equipment&v=1772513444019 "Schedule of future (projected) sales of companies in the market segment - Specialized medical equipment")
Future (projected) sales of the market as a whole
Embecta is a spinoff from Becton Dickinson, focusing entirely on diabetes treatment products such as syringes and needles. Demand for their products is very stable and driven by the chronic nature of the disease. This overall economic activity schedule has virtually no impact on the company's core business, which is driven by demographics and diabetes prevalence.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513444050 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Embecta Corp.
Embecta Corp., spun off from Becton Dickinson, is a pure-play player in the diabetes care market, primarily producing insulin syringes and needles. The company's profitability depends on its dominant position in this mature market and its production efficiency. The chart shows how the company, by focusing on a single segment, generates stable and predictable profits.
Market segment marginality - Specialized medical equipment
#VALUE!
Market marginality as a whole
Embecta Corp. specializes in producing products for people with diabetes, such as syringes and needles. Demand for its products is inelastic, as they are essential. This total profitability chart shows how resistant Embecta's business is to economic cycles. Its revenue is stable regardless of the overall health of the corporate sector.
Employees in the company, segment and market as a whole
Number of employees in the company Embecta Corp.
Embecta, a spinoff from Becton Dickinson, specializes in diabetes treatment products such as syringes and needles. Its sizeable workforce reflects the scale of its global production and sales. This chart shows the team size required to serve millions of diabetes patients worldwide.
Share of the company's employees Embecta Corp. within the market segment - Specialized medical equipment
Embecta Corp., a spinoff from Becton Dickinson, is a company dedicated entirely to diabetes care, specifically the production of insulin syringes and needles. As an established market leader, it has a significant manufacturing and global sales force. This chart reflects its scale and legacy operational strength in serving millions of patients worldwide.
Number of employees in the market segment - Specialized medical equipment
Embecta Corp., spun off from Becton Dickinson, is a pure-play player in the diabetes care market, primarily syringes and needles. Employment in the specialized medical equipment sector, shown here, reflects the scale of the diabetes problem. For Embecta, steady growth in this sector speaks to continued demand for their vital products.
Number of employees in the market as a whole
Embecta is a pure-play diabetes treatment company spun out of Becton Dickinson. Its business is built on the non-discretionary medical needs of a growing patient population. The company's labor requirements are stable and less susceptible to short-term economic cycles, as shown in this chart.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Embecta Corp. (EMBC)
Embecta, a spinoff from Becton Dickinson, specializes in diabetes products, specifically insulin syringes and needles. It is a mature and stable medical business. This metric reflects the efficiency of its large-scale manufacturing and established distribution network, which enable it to generate stable value.
%20of%20the%20company%20Embecta%20Corp.%20(EMBC)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Embecta-Corp.-EMBC&v=1772513444321 "Chart of market capitalization per employee (in thousands of dollars) of the company Embecta Corp. (EMBC)")
Market capitalization per employee (in thousands of dollars) in the market segment - Specialized medical equipment
Embecta, a spinoff from Becton Dickinson, specializes in diabetes treatment products such as injection pens. In the medical device sector, this metric reflects the value of its brand and patents. The graph shows how the market values its heritage and ability to generate stable revenue per employee.
%20by%20market%20segment%20-%20Specialized%20medical%20equipment&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Specialized-medical-equipment&v=1772513444338 "Market capitalization per employee (in thousands of dollars) by market segment - Specialized medical equipment")
Market capitalization per employee (in thousands of dollars) for the overall market
Embecta Corp., a spinoff from Becton Dickinson, is a leading company specializing in diabetes products, particularly injection pens. This chart shows how the market values this established medical device business. It reflects the efficiency of manufacturing and distributing a mass-market, life-saving product.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513444357 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Embecta Corp. (EMBC)
Embecta, a spinoff from Becton Dickinson, specializes exclusively in diabetes products (syringes, needles). It is a mature, stable medical business. This chart shows how effectively the company manages its legacy: the production and distribution of high-volume, low-margin medical supplies.
%20Chart%20Embecta%20Corp.%20(EMBC)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Embecta-Corp.-EMBC&v=1772513444369 "Company Profit Per Employee (in thousands of dollars) Chart Embecta Corp. (EMBC)")
Profit per employee (in thousands of dollars) in the market segment - Specialized medical equipment
Embecta, a spinoff from Becton Dickinson, focuses exclusively on diabetes treatment products (primarily insulin syringes and needles). It is a mature, large-scale medical device manufacturing business. This metric reflects its high operational efficiency in the mass production of standardized products.
%20in%20the%20market%20segment%20-%20Specialized%20medical%20equipment&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Specialized-medical-equipment&v=1772513444373 "Chart of profit per employee (in thousands of dollars) in the market segment - Specialized medical equipment")
Profit per employee (in thousands of dollars) for the market as a whole
Embecta Corp., a Becton Dickinson spinoff, specializes exclusively in diabetes products (syringes, needles for insulin pens). It operates a large-scale, highly automated medical manufacturing facility. This graph illustrates how high labor efficiency is achieved through automation and scale in the high-volume medical device manufacturing sector (where sterility and precision are essential).
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513444413 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Embecta Corp. (EMBC)
Embecta, spun off from Becton Dickinson, is a company focused entirely on diabetes treatment, producing insulin needles and syringes. Its revenue per employee reflects its leadership in this vast market. The graph shows robust demand for its life-saving products, which are used by millions of people with diabetes worldwide.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Embecta-Corp.-EMBC&v=1772513444456 "Sales chart per company employee Embecta Corp. (EMBC)")
Sales per employee in the market segment - Specialized medical equipment
Embecta (EMBC), spun off from Becton Dickinson, is a company focused entirely on diabetes treatment products, primarily insulin injection devices. This chart shows the average revenue per employee in the segment. It helps evaluate how effectively Embecta generates sales for its products compared to its competitors.
Sales per employee for the market as a whole
Embecta (EMBC), a spinoff from Becton Dickinson, specializes exclusively in diabetes treatment products, primarily insulin syringes and needles. It is a high-volume, highly automated manufacturer of medical devices. This metric demonstrates the enormous volume of critical yet low-cost products their factories generate per employee.
Short shares by company, segment and market as a whole
Shares shorted by company Embecta Corp. (EMBC)
Embecta (EMBC) is a Becton Dickinson spinoff focused exclusively on diabetes products, primarily insulin syringes and needles. This chart shows bearish sentiment. The surge in short positions may reflect concerns about traditional syringes being supplanted by more modern insulin pumps and smart pens. (340)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Embecta-Corp.-EMBC&v=1772513444523 "Short Shares Chart for the Company Embecta Corp. (EMBC)")
Shares shorted by market segment - Specialized medical equipment
Embecta is a syringe and needle business spun out of Becton Dickinson (BD). This chart shows the overall sentiment in the sector, reflecting investor concerns that new drugs (Ozempic) and CGM systems will reduce demand for traditional syringes.
Shares shorted by the overall market
Embecta (EMBC) is a spinoff from Becton Dickinson, focused entirely on diabetes products, primarily syringes and needles. It's a mature market, but one with intense competition and pricing pressure. This chart highlights concerns about the company's future as a standalone entity. Skeptics may fear that new technologies (insulin pumps) will make their products obsolete.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Embecta Corp. (EMBC)
Embecta is a Becton Dickinson spinoff focused exclusively on diabetes treatments (syringes and needles). It's a mature business, but vulnerable to disruptive technologies. This chart shows when the market is overselling the stock, fearing that insulin pumps and CGM will make their products obsolete, or overbuying it, valuing stable cash flow.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Embecta-Corp.-EMBC&v=1772513444629 "RSI 14 indicator chart for the company's stock Embecta Corp. (EMBC)")
RSI 14 Market Segment - Specialized medical equipment
Embecta, a spinoff from Becton Dickinson (BDX), specializes exclusively in diabetes treatment products, primarily insulin syringes and needles. This chart measures the overall momentum in the specialty medical equipment sector. It helps assess how the market views the industry and whether Embecta stands out from the crowd.
RSI 14 for the overall market
Embecta (EMBC) produces insulin syringes. This chart shows that its business is "defensive." Demand for its products isn't driven by euphoria or panic—it's driven by the number of diabetics. During times of market panic, investors seek safe havens in companies with completely non-cyclical demand, like EMBC.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast EMBC (Embecta Corp.)
Embecta (EMBC) is a company specializing in diabetes treatment products, primarily insulin syringes and needles. This chart shows the average target price. It reflects analysts' views on competition from new technologies (pumps) and the stability of demand for traditional diabetes care products.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-EMBC-Embecta-Corp.&v=1772513444788 "A chart showing analyst consensus forecasts for the expected stock price. EMBC (Embecta Corp.)")
The difference between the consensus estimate and the actual stock price EMBC (Embecta Corp.)
Embecta, spun off from BD, is a pure-play player in the diabetes care market, specializing in insulin syringes and needles. This chart shows how the current share price differs from analysts' "fair" value projections. It reflects their view of competition from pumps and new GLP-1 therapies.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-EMBC-Embecta-Corp.&v=1772513444871 "A chart showing the difference between the consensus forecast and the actual stock price. EMBC (Embecta Corp.)")
Analyst consensus forecast for stock prices by market segment - Specialized medical equipment
Embecta is a pure-play player in the diabetes market, spun off from BDX. The company dominates the production of syringes and needles for insulin pens. This chart shows analysts' overall expectations for the entire specialized medical equipment sector. It reflects whether experts believe the market is stable amid the growth of pumps and new medications (GLP-1).
Analysts' consensus forecast for the overall market share price
Embecta, a Becton Dickinson spinoff, focuses exclusively on diabetes products (syringes, needles). This is a mature, stable market. This chart shows the overall market sentiment. For Embecta, which operates in the defensive healthcare sector, these expectations (general noise) are less important than demographics and the prevalence of diabetes. (342)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Embecta Corp.
Embecta (EMBC) is a pure-play diabetes treatment business spun out of Becton Dickinson. Their core business is the production and sale of consumables (syringes, needles for insulin pens) for insulin injections. This chart is an indicator of their niche. It reflects the stable, demographic demand for their products, but also their struggle to innovate (new smart pens) in the face of competition from pumps.
AKIMA Market Segment Index - Specialized medical equipment
Embecta (EMBC) is a global leader in insulin delivery (spinned off from BDX); the company dominates the production of basic but essential consumables—insulin syringes and pen needles. This composite metric evaluates companies. The graph shows the sector average. This benchmark: how does this stable (razor-sharp) model (EMBC) differentiate it from its average medtech competitor?
The AKIM Index for the overall market
Embecta is a global leader in insulin delivery devices (pens, needles), spun off from BD. These are consumables for diabetics. This chart, reflecting the market average, is a backdrop. It helps assess how this stable, cash-generating business compares to the overall macroeconomic fluctuations reflected by this indicator.
